GlassScriptPhysician profile
Day Smith Lennep
NPI 1538509955
$12,547.51
in general payments reported to CMS, 2019-2025
30 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $784 · 2021: $1,442 · 2022: $1,722 · 2023: $2,262 · 2024: $2,554 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,216 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,216.14 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,708.29 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,391.86 | 2019-2025 | |
| Janssen Biotech, INC. | $1,228.07 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,065.81 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,000.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $676.12 | 2019-2025 | Benlysta |
| Pfizer INC. | $482.46 | 2019-2025 | |
| Radius Health, INC. | $450.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.45 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $347.53 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $338.89 | 2022-2025 | Acthar |
| Fresenius Kabi USA, LLC | $222.53 | 2023-2025 | Idacio |
| Lilly USA, LLC | $210.51 | 2019-2025 | Taltz, Zepbound |
| Ani Pharmaceuticals, INC. | $196.60 | 2023-2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $177.11 | 2019-2025 | Orencia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $108.89 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.54 | 2019-2023 | Cyltezo |
| Genentech USA, INC. | $97.11 | 2019-2023 | Actemra |
| Actelion Pharmaceuticals US, INC. | $60.99 | 2019-2022 | |
| Sobi, INC | $57.20 | 2019-2025 | |
| Organon LLC | $48.94 | 2023-2025 | Hadlima |
| Horizon Therapeutics Plc | $48.61 | 2023 | Krystexxa |
| Regeneron Healthcare Solutions, INC. | $27.80 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.91 | 2024 | Strensiq |
| Teva Pharmaceuticals USA, INC. | $20.05 | 2024 | Truxima |
| Hikma Pharmaceuticals USA | $19.34 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.06 | 2019 | |
| Irhythm Technologies, INC. | $16.16 | 2022 | |
| Genentech, INC. | $15.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Day Lennep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.